Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 15Cisplatin 13durvalumab 10pembrolizumab 9Oxaliplatin 8Magnetic Resonance Spectroscopy 8Specimen Handling 6Leucovorin 6Biopsy 6Fluorouracil 5Paclitaxel 4Folfox protocol 4Taxes 3Radiation 3Nivolumab 3Irinotecan 3Immunoglobulin G 3Disulfides 3tislelizumab 2pemigatinib 2olaparib 2futibatinib 2fludarabine 2dehydroftorafur 2Platinum 2Liver Transplantation 2Fluorodeoxyglucose F18 2Floxuridine 2Dexamethasone 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × KP 1339 × 90 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡